|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Malignant Mesothelioma | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Mesothelioma | |||||
| 3 | More general conditions related to this trial | ||||
| Adenoma | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Neoplasms, Mesothelial | |||||
| 4 | Interventions listed in this trial | ||||
| cisplatin | |||||
| pemetrexed disodium | |||||
| conventional surgery | |||||
| neoadjuvant therapy | |||||
| radiation therapy | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Pemetrexed | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antimetabolites | |||||
| Antimetabolites, Antineoplastic | |||||
| Antineoplastic Agents | |||||
| Enzyme Inhibitors | |||||
| Folic Acid Antagonists | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Radiation-Sensitizing Agents | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Memorial Sloan-Kettering Cancer Center | |||||
| National Cancer Institute (NCI) | |||||